Ovid Therapeutics surges after agreement in which Takeda will secure rights for soticlestat Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Ovid Therapeutics (OVID) and Takeda Pharmaceutical (TAK) up 89% and 3%, respectively, after announcing that Takeda has entered into an exclusive agreement under which it will secure global rights at closing from Ovid to develop and commercialize the investigational medicine soticlestat. Ovid will receive an upfront payment of $196M at closing and is eligible to receive up to an additional $660M upon achieving milestones
- KemPharm (KMPH) up 71% after announcing that the FDA has approved the new drug application for Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older
- Asensus Surgical (TRXC), formerly TransEnterix, up 33% after announcing the company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States.
UP AFTER EARNINGS -
- Cohen & Co. (COHN) up 40%
DOWN AFTER EARNINGS -
- Dycom (DY) down 4%
- Wendy's (WEN) down 3%
- Dollar Tree (DLTR) down 2%
- OneSpaWorld (OSW) down 4%
LOWER -
- Magnolia Oil & Gas (MGY) down 10% after its 17M share spot secondary priced at $10.50
Symbols:
OVID TAK KMPH TRXC DY WEN DLTR OSW MGY COHN ASXC Keywords: Fly Intel, Wall Street, Top Stories, Stocks